Breaking News
February 23, 2018 - Patients who achieve short-term weight loss before bariatric surgery have better outcomes
February 23, 2018 - Beetroot may reduce kidney failure risk after heart x-ray, research reveals
February 23, 2018 - Sleep disruptions in menopause correlated with hot flashes and depression
February 23, 2018 - Scientists discover new treatment approach to curb severe myocarditis
February 23, 2018 - ‘Click chemistry’ approach may improve disease-fighting properties of drugs
February 23, 2018 - NIGHTSEA and EMS team up to offer KEY Award in fluorescence stereo microscopy
February 23, 2018 - Tobacco Kills, No Matter How It’s Smoked: Study
February 23, 2018 - Q&A: Avindra Nath, MD | Medpage Today
February 23, 2018 - Adherence to sleep apnea treatment affects risk of hospital readmission
February 23, 2018 - Zika virus could be alternative for treatment of aggressive brain cancer
February 23, 2018 - Carbon monoxide enhances efficacy of antibiotic against stomach infection
February 23, 2018 - MSD and Ferring Pharmaceuticals Complete Largest Ever Clinical Trial in Postpartum Haemorrhage
February 23, 2018 - Portable ultrasound can help better detect fluid in the lungs of patients with end-stage kidney disease
February 23, 2018 - Postnova AF2000 system offers reliable characterization of trace metal colloid distribution in the environment
February 23, 2018 - Pioneering study may pave way for effective painkillers to treat neuropathic pain
February 23, 2018 - Research opens up new avenue to minimize risks of transplants
February 22, 2018 - Cabozantinib Active in Advanced Thyroid Cancer
February 22, 2018 - Polluted air may pollute our morality
February 22, 2018 - New data from VOYAGE 2 trial shows promising results for Janssen’s guselkumab treatment
February 22, 2018 - Bank loans signed in the hospital leave patients vulnerable
February 22, 2018 - Researchers identify new nanostructure inside sperm tails
February 22, 2018 - Catheter-based procedure increases treatment options for mitral valve disease
February 22, 2018 - Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder
February 22, 2018 - Larger Endocarditis Vegetations More Likely to Embolize, Kill
February 22, 2018 - Parenting behavior in adoptive families
February 22, 2018 - Researchers discover new weakness in sleeping sickness parasites
February 22, 2018 - Research project aims to find new ways to identify and treat most aggressive brain cancers
February 22, 2018 - Researchers explore how people with Alzheimer’s disease use end-of-life medical services
February 22, 2018 - Stroke survivors and carers feel marginalized due to lack of support from primary care
February 22, 2018 - Neuroscientists discover novel mechanism of action behind schizophrenia
February 22, 2018 - After shooting, ‘honor how kids want to deal with their feelings’
February 22, 2018 - U.S., EU and Japan Health Authorities Accept Regulatory Submissions For Review Of Pfizer’s Third-generation ALK Inhibitor Lorlatinib
February 22, 2018 - At-Home Genetic Test Might Change Medicine
February 22, 2018 - Many second hand plastic toys could pose a risk to children’s health, study suggests
February 22, 2018 - Study shows that two different brain systems cooperate during learning
February 22, 2018 - Liquefied brain tissue after stroke may harm surviving brain, UA study finds
February 22, 2018 - New intervention improves communication behaviors in couples affected by dementia
February 22, 2018 - Clinical trial shows safety of promising TSRI stroke drug
February 22, 2018 - Researchers discover new interaction mechanism of unstructured proteins
February 22, 2018 - A Patient’s Journey: Can I Kill the Glucose Monster?
February 22, 2018 - The Problem That Piles Up
February 22, 2018 - Kids can roll up their sleeves—again—for mumps protection
February 22, 2018 - Scientists find significant amounts of toxic metals in e-cigarette vapors
February 22, 2018 - 3D Signatures reports positive results of new Telo-HL test for Hodgkin’s lymphoma
February 22, 2018 - Scientists reveal development of improved medicine to fight addiction
February 22, 2018 - USC-led researchers release dataset of brain scans from stroke patients
February 22, 2018 - Antibiotic-producing bacterium releases more metabolites than assumed
February 22, 2018 - Flu Season Shows First Signs of Slowing
February 22, 2018 - Nonstick Chemicals May Disrupt Metabolic Function in Women
February 22, 2018 - Calcium may play a role in the development of Parkinson’s disease
February 22, 2018 - Scientists visualize insulin receptor activation for the first time
February 22, 2018 - UC San Diego Health now offers new treatment option for people with refractory epilepsy
February 22, 2018 - First African child vaccinated with new typhoid conjugate vaccine
February 22, 2018 - BetterYou named as ‘Most Innovative Brand’ at FGB Awards 2018
February 22, 2018 - Assaults Among Young People Fall to Lowest Rate in 15 Years
February 22, 2018 - What do you know about Parkinson’s disease?
February 22, 2018 - Researchers discover five new genetic changes that may increase pancreatic cancer risk
February 22, 2018 - Gout medication may help improve heart function in adult patients
February 22, 2018 - Bioactive compound limits collateral damage in the kidneys after heart attack
February 22, 2018 - Study reveals HCT as effective treatment for NHL patients regardless of age
February 22, 2018 - Father’s age can affect offspring lifespan, mice study shows
February 22, 2018 - Opiant Pharmaceuticals Announces Publication of New Pre-Clinical Data Supporting Potential of OPNT005 as a Heroin Vaccine
February 22, 2018 - Make the Diagnosis: Strange Rash Surfaces
February 22, 2018 - Isolated sulfite oxidase deficiency – Genetics Home Reference
February 22, 2018 - Scientists identify weight loss ripple effect
February 22, 2018 - Smoking at record lows in New York
February 22, 2018 - Scientists pinpoint fertility hormone that could support early pregnancy
February 22, 2018 - Aggressive cancer stem cells can now be isolated successfully in a scientific breakthrough
February 22, 2018 - Researchers find high risk of suicide among unaccompanied refugee minors
February 22, 2018 - Protein levels linked to posture and gait problems in Parkinson’s
February 22, 2018 - Biomedical engineers create 3D hydrogel scaffolds  to transform cells into muscle
February 22, 2018 - Study employs novel approach to uncover new biomarker for CHD
February 22, 2018 - Study finds strong connection between midwifery and birth outcomes
February 22, 2018 - Verastem Submits NDA to FDA for Duvelisib for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma
February 22, 2018 - Low BP Associated With Risk in HFpEF
February 22, 2018 - More U.S. women obese before pregnancy, experts sound the alarm
February 22, 2018 - Study aims to examine effects of PTSD symptoms in police officers
February 22, 2018 - Study reveals increased disease risk after early heart surgery
February 22, 2018 - Women with Type 1 diabetes come across unique challenges
February 22, 2018 - Researchers target abnormal epigenetic mechanisms involved in childhood cancers
New treatment aims to target abnormally shaped protein in deadly childhood brain cancer

New treatment aims to target abnormally shaped protein in deadly childhood brain cancer

image_pdfDownload PDFimage_print

Children with an extremely deadly form of brain cancer might benefit from a new treatment that aims to direct an immune response against an abnormally shaped protein found exclusively on cancer cells, according to a new study led by UC San Francisco researchers.

The focus of the study, published online December 4, 2017 in the Journal of Experimental Medicine, is diffuse intrinsic pontine glioma (DIPG), an aggressive pediatric brain cancer. DIPG is rare — estimates suggest that about 300 new cases occur in the United States each year — but almost always fatal.

Because DIPG occurs in a difficult-to-access area of the brain stem that controls vital functions such as breathing, blood pressure, and heart rate, these tumors are almost impossible to remove surgically. Radiation therapy is the current standard treatment, but is rarely effective for long, according to Hideho Okada, MD, PhD, professor of neurological surgery and director of the Brain Tumor Immunotherapy Center at UCSF, and the senior author of the study.

“It is important to develop more innovative treatment approaches for childhood brain cancers, which now are the leading cause of cancer death in children. DIPG is a very deadly type of brain cancer, and not many children survive beyond 12 months from the time of diagnosis.” said Okada, also a member of the Helen Diller Family Comprehensive Cancer Center (HDFCC) at UCSF and of the Parker Institute for Cancer Immunotherapy.

Okada, along with Sabine Mueller, MD, PhD, MAS, an assistant professor of clinical neurology at UCSF and a HDFCCC member, already are leading a phase I clinical trial in children with DIPG and closely related gliomas, in order to evaluate a new anti-tumor vaccine based on the new target identified by Okada’s research group.

The new study’s preclinical results also support the development of an immunotherapy treatment that is potentially more powerful than a simple vaccine, one in which some of the patient’s own immune cells would be genetically engineered to recognize the molecular target, which is found on tumor cells in most cases of DIPG and related gliomas, but not on normal cells.

The immune system needs a boost to fight established tumors. Normally it can distinguish a healthy cell from a cell infected by invading pathogens by inspecting bits of molecules, called antigens, which cells display on their outer surface. Very early in life the immune system learns to tolerate rather than to attack cells displaying antigens made by the body’s own cells. Because tumors arise from our own cells, the immune system is likely to tolerate rather than attack the cells of an established tumor.

The target of the new DIPG treatment is a “neoantigen.” A neoantigen is a fragment of a protein made by a cancer cell that has an abnormal structure — and often an abnormal function — due to genetic mutation, a hallmark of cancer. Researchers are developing techniques to select neoantigens that they think will be the most likely to be seen and identified as foreign by the immune system, and they aim to develop immunotherapies to boost immune responses to tumor cells displaying these neoantigens.

Tumors often have a large variety of mutated proteins, but many of these proteins are too similar to normal antigens for the immune system to recognize them as a threat. Even if the immune system can be coaxed to attack cells displaying a fragment of these mutant proteins, it might also learn to attack healthy cells displaying the protein’s normal counterpart. In fact, autoimmunity is a risk for many patients given current immunotherapies, such as “checkpoint inhibitors,” which release the brakes that prevent the immune system from attacking tumor cells.

The hope is that well-chosen neoantigens can be used to develop treatments that will more selectively and potently target tumors. Neoantigen-based treatments are still experimental, but many are in clinical trials.

The neoantigen Okada and colleagues worked with is a fragment of a protein called histone 3 variant 3. This protein is identically mutated in about 70 percent of cases of DIPG and results in abnormal control of gene activity in tumor cells. Earlier studies by other researchers found that when the mutation is present, it is present in all, or nearly all cells of the tumor.

“This may be an ideal case of a tumor neoantigen,” Okada, said. “Most neoantigens in cancer are unique to individual patients, but this is one of very, very few examples of a shared, common neoantigen that may have the potential to be used in many patients.”

The researchers used some of the latest computational techniques to predict that a specific fragment of the protein that includes the neoantigen would bind especially strongly to a protein called HLA A, which displays antigens for inspection by patrolling immune cells called T cells. The strength of this attachment ought to correspond to the likelihood that a neoantigen will be recognized as a threat by the immune system.

In laboratory experiments the researchers confirmed this prediction. They found a strong affinity between the tumor neoantigen and a type of HLA A found in about 40 percent of DIPG patients. In contrast, they found no corresponding affinity between this HLA A type and non-mutated antigens from related proteins produced by healthy cells, suggesting that treatments based on this neoantigen should be specific to tumor cells only.

The goal of the neoantigen-containing vaccine now being tested in Okada and Mueller’s clinical trial is to train the immune system’s T cells to recognize the neoantigen in the vaccine, which should then trigger an immune response to tumor cells in the brain that display the same neoantigen, Okada said.

The new paper also demonstrates a promising, even more powerful form of treatment based on directly engineering patients’ T cells to recognize the target neoantigen. Every T cell has a particular type of T cell receptor protein that can recognize a single antigen paired with an HLA protein. The scientists used T cells from patients with the HLA A type that bound tightly to the novel DIPG neoantigen to identify naturally arising T cell receptors that recognize the combination. They selected the best T cell receptor, cloned it into other T cells, and grew large numbers of these cells in the lab. They then demonstrated that these lab-grown T cells could effectively kill human glioma tumors grown in mice.

“We saw a significant reduction in tumor progression compared to control groups,” said tumor immunologist Zinal Chheda, PhD, a postdoctoral fellow with Okada’s lab and the co-lead author of the study. “The T cell receptor we selected for cloning has an affinity for the neoantigen that is in the range of what we see for antigens from viruses — orders of magnitude greater than what we generally see with neoantigens found on cancer cells.”

Source:

https://www.ucsf.edu/news/2017/12/409181/new-immunotherapy-targets-misshapen-protein-rare-childhood-brain-cancer

Tagged with:

About author

Related Articles